Form 8-K

8-K — Perspective Therapeutics, Inc.

Accession: 0001193125-26-429770

Filed: 2026-10-23

Period: 2026-10-23

CIK: 0000728387

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — catx-20261023.htm (Primary)

EX-99.1 (catx-ex99_1.htm)

EX-99.2 (catx-ex99_2.htm)

GRAPHIC (img236230851_0.gif)

GRAPHIC (catx-ex99_2s1.jpg)

GRAPHIC (catx-ex99_2s2.jpg)

GRAPHIC (catx-ex99_2s3.jpg)

GRAPHIC (catx-ex99_2s4.jpg)

GRAPHIC (catx-ex99_2s5.jpg)

GRAPHIC (catx-ex99_2s6.jpg)

GRAPHIC (catx-ex99_2s7.jpg)

GRAPHIC (catx-ex99_2s8.jpg)

GRAPHIC (catx-ex99_2s9.jpg)

GRAPHIC (catx-ex99_2s10.jpg)

GRAPHIC (catx-ex99_2s11.jpg)

GRAPHIC (catx-ex99_2s12.jpg)

GRAPHIC (catx-ex99_2s13.jpg)

GRAPHIC (catx-ex99_2s14.jpg)

GRAPHIC (catx-ex99_2s15.jpg)

GRAPHIC (catx-ex99_2s16.jpg)

GRAPHIC (catx-ex99_2s17.jpg)

GRAPHIC (catx-ex99_2s18.jpg)

GRAPHIC (catx-ex99_2s19.jpg)

GRAPHIC (catx-ex99_2s20.jpg)

GRAPHIC (catx-ex99_2s21.jpg)

GRAPHIC (catx-ex99_2s22.jpg)

GRAPHIC (catx-ex99_2s23.jpg)

GRAPHIC (catx-ex99_2s24.jpg)

GRAPHIC (catx-ex99_2s25.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: catx-20261023.htm · Sequence: 1

8-K

0000728387false00007283872026-10-232026-10-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-33407

41-1458152

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

Seattle, Washington

98121

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CATX

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 23, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors that are being presented at the European Society for Medical Oncology Congress 2026 taking place October 23-27, 2026 in Madrid, Spain. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated October 23, 2026.

99.2

Presentation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PERSPECTIVE THERAPEUTICS, INC.

Date:

October 23, 2026

By:

/s/ Johan (Thijs) Spoor

Johan (Thijs) Spoor

Chief Executive Officer

EX-99.1

Filename: catx-ex99_1.htm · Sequence: 2

EX-99.1

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

•

Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NET

•

Durable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatment

•

Robust activity observed at three dose levels across patient populations, with ORRs of 33% and 50% in Cohorts 2 and 3, respectively; higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments

•

[212Pb]VMT-α-NET continues to be well-tolerated, with no DLTs, and no discontinuations due to adverse events

•

Aiming to complete Phase 3 site start-up preparations around year-end 2026, positioning us to rapidly activate clinical sites following regulatory alignment

•

Conference call to be webcast today at 2 pm EDT / 8 pm CEST (join here)

SEATTLE, Oct. 23, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These data are being presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026 in Madrid, Spain.

Neuroendocrine tumors are diagnosed in more than 12,000 people in the United States each year, and approximately 90% of gastroenteropancreatic (GEP) NETs express SSTR2, the target of [²¹²Pb]VMT-α-NET. In the ongoing Phase 1/2a study in patients with SSTR2-positive NETs who had not received prior radiopharmaceutical therapy, the objective response rate (ORR), including unconfirmed responses, was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026). For GEP-NETs patients with SSTR2 expression in all target lesions, responses were seen in 14 (37%) of 38 Cohort 2 patients, and in eight (47%) of 17 Cohort 3 patients. Disease control rate (DCR) was 89% and 95% in Cohorts 2 and 3, respectively, and progression-free survival (PFS) was 72% at 18 months across all cohorts. No dose-limiting toxicities (DLTs), Grade 4 or 5 treatment-emergent adverse events (TEAEs), or adverse event-related treatment discontinuations were reported. We aim to complete Phase 3 site start-up preparations around year-end 2026, positioning us to rapidly activate clinical sites following an End-of-Phase 2 meeting with the FDA, with Phase 3 initiation expected in 2027.

“These interim results reinforce the potential of VMT-α-NET to achieve a best-in-class profile, with robust tumor response, durable disease control and low incidence of high-grade adverse events,” said Thijs Spoor, Perspective’s Chief Executive Officer. “Success in radiopharmaceuticals requires a broad therapeutic window, and these data show our platform delivers: potent alpha radiation concentrated in the tumor, with tolerability that holds up across dose levels. Preparations for our first potential Phase 3 study are advancing, and we look forward to discussing the development plan with the FDA as we work toward the next stage of development.”

“These data from a substantially larger group of patients and longer follow-up provide a more comprehensive understanding of the clinical profile of VMT-α-NET,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “We are very pleased with the evidence of sustained disease control alongside an encouraging safety profile observed to date, supporting VMT-α-NET’s potential in patients with SSTR2-positive neuroendocrine tumors. With regulatory engagement underway and manufacturing capacity scaling in parallel, we’re working to bring a potentially transformative new option to patients who need more choices.”

ESMO presentation based on analysis of 68 patients across three dose cohorts

The presentation provided initial cohort-level safety data in Cohorts 1, 2, and 3 of the study, as well as updated efficacy results from both patients in Cohort 1 (up to four treatments with 2.5 mCi of [²¹²Pb]VMT-α-NET), and initial results from all 46 patients in Cohort 2 (up to four treatments with 5.0 mCi) and all 20 patients in Cohort 3 (up to four treatments with 6.0 mCi). The analysis data cut-off date was September 2, 2026, approximately 20 weeks after the ASCO 2026 data cut-off date.

Efficacy: Objective responses in Cohorts 2 and 3, with disease control in at least 89% of patients in each cohort

Cohort 1

2.5 mCi (n=2)

Cohort 2

5.0 mCi (n=46)

Cohort 3

6.0 mCi (n=20)

Objective response rate

0 of 2 (0%)

15 of 46 (33%)

10 of 20 (50%)*

Disease control rate

2 of 2 (100%)

41 of 46 (89%)

19 of 20 (95%)

Objective response rate in GEP-NET patients whose target lesions all express SSTR2

0 of 2 (0%)

14 of 38 (37%)

8 of 17 (47%)*

*Includes two additional unconfirmed partial responses reported as of September 10, 2026. Objective response rate includes confirmed and unconfirmed responses. Disease control rate includes complete response, partial response, and stable disease. Cohort size and follow-up differ across cohorts.

•

Durable disease control: PFS rate was 86% at six months, 74% at 12 months, and 72% at 18 months across Cohorts 1, 2, and 3.

•

Cohort 2: Robust tumor response observed. Fifteen out of 46 (33%) patients experienced an initial response; 14 of those responses were confirmed. One patient experienced an initial response 72 weeks after their first treatment, remains on study, and is expected to receive subsequent tumor assessment. A further 13 patients with stable disease in Cohort 2 remain in study as of September 10, 2026.

•

Cohort 3: Higher responses were observed in Cohort 3 relative to Cohort 2 at early assessments. Ten out of 20 (50%) patients in Cohort 3 experienced an initial response, with eight responses occurring as of September 2, 2026 and two more reported as of September 10, 2026. Five of those responses were confirmed as of September 2, 2026, and an additional response was confirmed as of September 10, 2026. All four patients with responses pending confirmation remain on study and are expected to receive subsequent tumor assessment. A further eight patients with stable disease in Cohort 3 remain in study as of September 10, 2026.

•

GEP-NET patients whose target lesions all express SSTR2: Responses were seen in 14 (37%) of 38 Cohort 2 patients, and in eight (47%) of 17 Cohort 3 patients.

Safety: No dose-limiting toxicities and no discontinuations due to adverse events

•

[212Pb]VMT-α-NET continues to be well-tolerated.

•

There were no reports of DLTs, no treatment-related discontinuations, and no serious adverse events (SAEs) related to the study medication during the TEAE window at this point in the study.

•

A low incidence of high-grade TEAEs (20 out of 68 patients, or 29%) was observed, all of which were Grade 3.

•

No dysphagia and no myelodysplastic syndrome were reported.

•

Two patients (2.9%) had Grade 3 renal events, and renal function continues to be characterized over longer follow-up.

Additional data presentations at upcoming conferences

The Company will present additional data in the coming weeks: at the NANETS 2026 Multidisciplinary NET Medical Symposium, November 5, 2026, and the EORTC-NCI-AACR (ENA) Symposium, November 20, 2026.

Conference call today

Perspective will webcast a conference call today at 2 pm EDT / 8 pm CEST to discuss the data presented at the ESMO Congress 2026. Webcast details are available on the Events page of the Company's website. A question-and-answer session will follow the formal presentation.

About [²¹²Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

About Neuroendocrine Tumors

Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs, and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors, and as a result, there are over 250,000 people living with this diagnosis.1

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s proprietary technology, imaging techniques and product candidates, including VMT-α-NET, PSV359, and VMT01, and related treatment opportunities in connection therewith; the Company’s understanding regarding the clinical profiles of its product candidates, including VMT-α-NET, PSV359, and VMT01; the Company’s belief that interim data reinforce the best-in-class potential of VMT-α-NET; the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the anticipated clinical benefits of the Company’s product candidates relative to existing therapies; the Company’s expectations regarding regulatory engagement and pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies, including the FDA, and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include (without limitation) that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; regulatory authorities may not grant or may delay approval for our product candidates; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; the Company’s ability to successfully prepare for and initiate a registrational Phase 3 clinical trial of VMT-α-NET, including whether the FDA agrees with the Company’s proposed Phase 3 development plan; whether the Company will be able to initiate the anticipated Phase 3 trial in 2027; the Company’s ability to establish, maintain and expand its regional distribution and manufacturing capabilities; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

ENTENTE Network of Companies

Katie Morris, PhD

katiemorris@ententeinc.com

1Dasari A et al. JAMA Netw Open 2025;8:e2515798.

EX-99.2

Filename: catx-ex99_2.htm · Sequence: 3

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for Bamzireotide Navoxetan

GRAPHIC

Filename: img236230851_0.gif · Sequence: 4

Binary file (9943 bytes)

Download img236230851_0.gif

GRAPHIC

Filename: catx-ex99_2s1.jpg · Sequence: 5

Binary file (145454 bytes)

Download catx-ex99_2s1.jpg

GRAPHIC

Filename: catx-ex99_2s2.jpg · Sequence: 6

Binary file (411823 bytes)

Download catx-ex99_2s2.jpg

GRAPHIC

Filename: catx-ex99_2s3.jpg · Sequence: 7

Binary file (333765 bytes)

Download catx-ex99_2s3.jpg

GRAPHIC

Filename: catx-ex99_2s4.jpg · Sequence: 8

Binary file (239292 bytes)

Download catx-ex99_2s4.jpg

GRAPHIC

Filename: catx-ex99_2s5.jpg · Sequence: 9

Binary file (189354 bytes)

Download catx-ex99_2s5.jpg

GRAPHIC

Filename: catx-ex99_2s6.jpg · Sequence: 10

Binary file (432029 bytes)

Download catx-ex99_2s6.jpg

GRAPHIC

Filename: catx-ex99_2s7.jpg · Sequence: 11

Binary file (278617 bytes)

Download catx-ex99_2s7.jpg

GRAPHIC

Filename: catx-ex99_2s8.jpg · Sequence: 12

Binary file (232487 bytes)

Download catx-ex99_2s8.jpg

GRAPHIC

Filename: catx-ex99_2s9.jpg · Sequence: 13

Binary file (201702 bytes)

Download catx-ex99_2s9.jpg

GRAPHIC

Filename: catx-ex99_2s10.jpg · Sequence: 14

Binary file (226765 bytes)

Download catx-ex99_2s10.jpg

GRAPHIC

Filename: catx-ex99_2s11.jpg · Sequence: 15

Binary file (213872 bytes)

Download catx-ex99_2s11.jpg

GRAPHIC

Filename: catx-ex99_2s12.jpg · Sequence: 16

Binary file (120586 bytes)

Download catx-ex99_2s12.jpg

GRAPHIC

Filename: catx-ex99_2s13.jpg · Sequence: 17

Binary file (121302 bytes)

Download catx-ex99_2s13.jpg

GRAPHIC

Filename: catx-ex99_2s14.jpg · Sequence: 18

Binary file (308517 bytes)

Download catx-ex99_2s14.jpg

GRAPHIC

Filename: catx-ex99_2s15.jpg · Sequence: 19

Binary file (257545 bytes)

Download catx-ex99_2s15.jpg

GRAPHIC

Filename: catx-ex99_2s16.jpg · Sequence: 20

Binary file (224702 bytes)

Download catx-ex99_2s16.jpg

GRAPHIC

Filename: catx-ex99_2s17.jpg · Sequence: 21

Binary file (122654 bytes)

Download catx-ex99_2s17.jpg

GRAPHIC

Filename: catx-ex99_2s18.jpg · Sequence: 22

Binary file (343388 bytes)

Download catx-ex99_2s18.jpg

GRAPHIC

Filename: catx-ex99_2s19.jpg · Sequence: 23

Binary file (208370 bytes)

Download catx-ex99_2s19.jpg

GRAPHIC

Filename: catx-ex99_2s20.jpg · Sequence: 24

Binary file (408964 bytes)

Download catx-ex99_2s20.jpg

GRAPHIC

Filename: catx-ex99_2s21.jpg · Sequence: 25

Binary file (415564 bytes)

Download catx-ex99_2s21.jpg

GRAPHIC

Filename: catx-ex99_2s22.jpg · Sequence: 26

Binary file (331122 bytes)

Download catx-ex99_2s22.jpg

GRAPHIC

Filename: catx-ex99_2s23.jpg · Sequence: 27

Binary file (302380 bytes)

Download catx-ex99_2s23.jpg

GRAPHIC

Filename: catx-ex99_2s24.jpg · Sequence: 28

Binary file (371685 bytes)

Download catx-ex99_2s24.jpg

GRAPHIC

Filename: catx-ex99_2s25.jpg · Sequence: 29

Binary file (326939 bytes)

Download catx-ex99_2s25.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 32

v3.26.3

Document And Entity Information

Oct. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 23, 2026

Entity Registrant Name

Perspective Therapeutics, Inc.

Entity Central Index Key

0000728387

Entity Emerging Growth Company

false

Entity File Number

001-33407

Entity Incorporation, State or Country Code

Entity Tax Identification Number

41-1458152

Entity Address, Address Line One

c/o Perspective Therapeutics, Inc.

Entity Address, Address Line Two

2401 Elliott Avenue

Entity Address, Address Line Three

Suite 320

Entity Address, City or Town

Seattle

Entity Address, State or Province

Entity Address, Postal Zip Code

98121

City Area Code

(206)

Local Phone Number

676-0900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CATX

Security Exchange Name

NYSEAMER

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration